Spots Global Cancer Trial Database for canakinumab
Every month we try and update this database with for canakinumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | NCT04028245 | Carcinoma, Rena... | Spartalizumab Canakinumab | 18 Years - 99 Years | Columbia University | |
| A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | NCT04028245 | Carcinoma, Rena... | Spartalizumab Canakinumab | 18 Years - 99 Years | Columbia University | |
| This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. | NCT03968419 | Non-small Cell ... | Canakinumab Pembrolizumab | 18 Years - | Novartis | |
| A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer | NCT04905316 | Non-small Cell ... | Canakinumab Durvalumab Radiation thera... Chemotherapy | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer | NCT05725343 | Lung Cancer | Canakinumab Placebo | 18 Years - 75 Years | Mario Negri Institute for Pharmacological Research | |
| Evaluation of Canakinumab in High-Risk Former-Smokers | NCT06038526 | Cigarette Smoki... Lung Carcinoma | Biospecimen Col... Bronchoscopy Canakinumab Carbon Monoxide... Survey Administ... | 55 Years - 73 Years | Ohio State University Comprehensive Cancer Center | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS | NCT04810611 | Myelodysplastic... | MBG453 NIS793 canakinumab | 18 Years - | Novartis | |
| A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies | NCT02334748 | Systemic Juveni... Hereditary Peri... | canakinumab | 5 Years - 20 Years | Novartis | |
| Study of Canakinumab in Patients With Myelofibrosis | NCT05467800 | Primary Myelofi... Post-essential ... ET-MF Post-polycythem... PV-MF | Canakinumab | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | NCT04239157 | Chronic Myelomo... Myelodysplastic... Recurrent Chron... Recurrent Myelo... Refractory Chro... Refractory Myel... | Canakinumab | 18 Years - | M.D. Anderson Cancer Center | |
| PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | NCT03064854 | Non-small Cell ... | PDR001 Cisplatin Gemcitabine Pemetrexed Carboplatin Paclitaxel Canakinumab | 18 Years - | Novartis | |
| PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | NCT03064854 | Non-small Cell ... | PDR001 Cisplatin Gemcitabine Pemetrexed Carboplatin Paclitaxel Canakinumab | 18 Years - | Novartis | |
| Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study | NCT05641831 | Clonal Cytopeni... | Biospecimen Col... Bone Marrow Asp... Canakinumab Chest Radiograp... Echocardiograph... Placebo Adminis... Quality-of-Life... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy | NCT03626545 | Non-Small-Cell ... | Canakinumab Docetaxel Placebo | 18 Years - | Novartis | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects | NCT03631199 | Non-small Cell ... | canakinumab canakinumab mat... pembrolizumab carboplatin cisplatin paclitaxel nab-paclitaxel pemetrexed | 18 Years - | Novartis | |
| Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy | NCT03626545 | Non-Small-Cell ... | Canakinumab Docetaxel Placebo | 18 Years - | Novartis | |
| A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer | NCT05725343 | Lung Cancer | Canakinumab Placebo | 18 Years - 75 Years | Mario Negri Institute for Pharmacological Research |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
